Insights & Resources

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

AI is revolutionizing industries, but misleading claims are rampant. Learn how the SEC combats AI washing and the importance of transparency for investment advisers.

In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.

How can financial institutions monitor social media activity and initiate a strategy to resolve issues timely enough to not be outpaced? Consider these steps:

Whether you are a buyer or a seller, we can help you model the tax consequences of a transaction & determine the impact of making a Section 338(h)(10) election for an acquisition.

By offsetting payroll taxes, the R&D tax credit can be an immediate source of cash for tech companies and others that qualify.